PRE PRE
Company Profile ↓Company Overview
PRE (PRE) is a publicly traded company listed on with a market capitalization of $311.50M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 91.5% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $92.39M (+479.8% YoY); net profit $-37.71M.
- Trailing 12 Months Year-on-year growth — revenue +479.8%.
- 5-Year Trend Long-term compounding — revenue CAGR 91.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 91.46% |
| 1 Year: | 479.76% |
Stock Price Performance
| 1 Year: | +136.21% |
| 6 Months: | -5.19% |
| 3 Months: | +10.34% |
| 1 Month: | +9.95% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)47.19 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 91.5% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 8.28M | 17.68M | 23.55M | 36.56M | 35.95M |
| Cost of Revenue | - | 2.67M | 10.39M | 9.53M | 14.97M | 12.67M |
| Gross Profit | - | 5.61M | 7.29M | 14.02M | 21.59M | 23.28M |
| Operating Expenses | - | 11.78M | 17.16M | 20.58M | 34.72M | 32.99M |
| Operating Income | - | -6.17M | -9.87M | -6.56M | -13.14M | -9.71M |
| EBITDA | - | -5.04M | -9.33M | -6.72M | -9.61M | -9.52M |
| Interest Expense | 78.63K | 69.00K | 65.00K | 55.00K | 45.00K | - |
| Pretax Income | - | -6.05M | -10.95M | -6.78M | -9.66M | -27.31M |
| Tax Provision | - | 20.00K | -33.00K | 9.00K | 38.00K | 28.00K |
| Net Income | - | -10.39M | -12.41M | -7.41M | -7.50M | -23.10M |
| Diluted EPS | - | -0.80 | -0.94 | -0.53 | - | -1.36 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 13.16M | 6.16M | 15.94M | 92.39M |
| Cost of Revenue | - | 9.55M | 4.98M | 6.66M | 43.60M |
| Gross Profit | - | 3.62M | 1.17M | 9.28M | 48.79M |
| Operating Expenses | - | 69.53M | 43.64M | 47.55M | 86.92M |
| Operating Income | - | -65.92M | -42.47M | -38.28M | -38.13M |
| EBITDA | - | -218.04M | -35.10M | -39.93M | -32.19M |
| Interest Expense | - | 242.00K | 46.00K | 168.00K | 241.00K |
| Pretax Income | - | -225.82M | -42.94M | -46.02M | -36.21M |
| Tax Provision | - | -245.00K | 54.00K | -7.64M | 34.00K |
| Net Income | - | -190.45M | -62.72M | -46.30M | -37.71M |
| Diluted EPS | - | -37.50 | -5.58 | -3.71 | -4.15 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 312.13M | 254.17M | 213.57M | 206.07M |
| Current Assets | - | 241.81M | 93.66M | 86.15M | 85.20M |
| Cash & Equivalents | - | 146.66M | 45.71M | 52.25M | 32.13M |
| Inventory | - | 4.53M | 3.13M | 6.57M | 7.03M |
| Receivables | - | 41.69M | 4.06M | 5.24M | 2.98M |
| Total Liabilities | - | 68.67M | 44.01M | 42.23M | 49.71M |
| Current Liabilities | - | 57.20M | 39.48M | 36.55M | 28.71M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 6.65M | 2.37M | 5.77M | 1.77M |
| Total Equity | - | 237.06M | 206.36M | 170.39M | 156.46M |
| Shares Outstanding | - | 9.13M | 12.22M | 12.98M | 16.87M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 14.52M | -13.77M | -28.87M | -21.83M |
| Investing Cash Flow | - | -46.15M | -82.95M | 38.54M | -35.69M |
| Financing Cash Flow | - | 143.32M | -4.70M | -3.34M | 37.47M |
| Capital Expenditure | - | -6.34M | -912.00K | -1.06M | -54.56M |
| Free Cash Flow | - | 8.17M | -14.68M | -29.94M | -76.39M |
| Net Change in Cash | - | 111.69M | -101.42M | 6.32M | -20.05M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 27.5% | 19.1% | 58.2% | 52.8% |
| Operating Margin % | - | -500.7% | -690.0% | -240.2% | -41.3% |
| Net Margin % | - | -1,446.8% | -1,019.1% | -290.6% | -40.8% |
| ROE % | - | -80.3% | -30.4% | -27.2% | -24.1% |
| ROCE % | - | -25.9% | -19.8% | -21.6% | -21.5% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PRE
PRE Continues to Exceed Expectations and Receive Preferential Financing
By Brad Sorensen, CFA NASDAQ: PRE READ THE FULL PRE RESEARCH REPORT Prenetics Global (NASDAQ: PRE) delivered one of its most significant strategic financing announcements to date, securing a $1 billion growth financing commitment from Gener…
Sector Update: Healthcare Stocks Fall Late Afternoon
Healthcare stocks fell late Tuesday afternoon with the NYSE Healthcare Index declining 1.7% and the
Prenetics’ IM8 Secures $1 Billion Growth Financing from General Catalyst’s Customer Value Fund (CVF)
IM8 is the fastest-growing premium supplement brand ever recorded — over 50 million servings delivered to date, with approximately 200,000 servings currently delivered daily, and an order every 27 secondsPrenetics raises full-year 2026 IM8 …
Prenetics Global Limited (PRE) Receives Bullish Coverage as IM8 Targets Supplement Market Growth
We recently compiled a list of the 10 Most Promising Small-Cap Stocks to Buy According to Hedge Funds. Prenetics Global Limited (NASDAQ:PRE) is one of the most promising stocks on our list. TheFly reported on June 16 that Benchmark initiate…
CEO Chat with Danny Yeung, Co-Founder and CEO of Prenetics Global
NASDAQ: PRE Brad Sorensen, CFA: Hello, everyone. Thank you for joining us. I'm really thrilled to be here. I'm Brad Sorensen, CFA, Senior Analyst here with Zacks Small Cap Research , and I'm thrilled to be joined by the CEO of Prenetics Glo…
Sector Update: Healthcare Stocks Decline Late Afternoon
Healthcare stocks fell late Wednesday afternoon with the NYSE Healthcare Index declining 0.8% and th
PRE — Frequently Asked Questions
What is the current share price of PRE?
As of 2026-08-05 17:25 PDT, PRE trades at $18.46 on NASDAQ/NYSE. Its 52-week range is $7.25 to $22.15.
What is the market capitalisation of PRE?
PRE has a market capitalisation of $311.50M on NASDAQ/NYSE.
What is the P/E ratio of PRE?
PRE trades at a trailing price-to-earnings (P/E) ratio of -4.45. Its price-to-book (P/B) ratio is 1.99.
What is the return on equity (ROE) of PRE?
PRE has a return on equity (ROE) of -24.10%. Its return on capital employed (ROCE) is -21.50%.
Is PRE a good stock to buy?
This page provides a data-driven analysis of PRE, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.